A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia

BACKGROUND: Chronic myeloid leukaemia (CML) is characterised by the presence of a fusion driver oncogene, BCR-ABL1, which is a constitutive tyrosine kinase. Tyrosine kinase inhibitors (TKIs) are the central treatment strategy for CML patients and have significantly improved survival rates, but the T...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Oncol
Asıl Yazarlar: Korfi, K., Mandal, A., Furney, S. J., Wiseman, D., Somervaille, T. C. P., Marais, R.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2015
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4516045/
https://ncbi.nlm.nih.gov/pubmed/25712455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv110
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller